MedTrace Logo

Study to Evaluate MET642 in Patients With NASH

NCT04773964 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2024-03-28

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

MET642

MET642 active treatment

DRUG

Placebo

Placebo comparator

Sponsors & Collaborators

  • Metacrine, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04773964 on ClinicalTrials.gov